Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Arthritis Rheumatol. 2016 Aug;68(8):1964–1969. doi: 10.1002/art.39668

Figure 1. Measurement of aPL tests through pregnancy according to aPL positivity at baseline.

Figure 1

Patients are classified according to positivity for each aPL test at baseline.

A. Variation in aCL titers, among aCL-positive patients at screening (n=90 for IgG and n=29 for IgM). B. Variation in aβ2GPI titers, among aβ2GPI-positive patients at screening (n=59 for IgG and n=26 for IgM). C. Variation in aCL titers, among aCL-negative patients at screening (n=59 for IgG and n=120 for IgM). D. Variation in aβ2GPI titers, among aβ2GPI-negative patients at screening (n=89 for IgG and n=122 for IgM).

aPL positivity was defined for each test. aCL: IgG ≥40 GPL units; IgM ≥40 MPL units; and anti-β2GPI: IgG ≥40 GPL units; IgM ≥40 MPL units. To be considered positive, each test met these criteria at least twice between 6 weeks and 5 years apart, with one determination during the PROMISSE pregnancy at a core lab (4). Negative aCL or aβ2GPI titers were defined as <40 GPL or MPL units.

Values represent mean ± SEM. *p<0.05 **p<0.01 compared to screening using Wilcoxon-Paired test.

Abbreviations: aCL: Anticardiolipin antibodies; aβ2GPI: anti-β2 Glycoprotein I antibodies